Literature DB >> 23271355

Management of neutropenia in cancer patients.

Maryam B Lustberg.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23271355      PMCID： PMC4059501     

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN： 1543-0790


× No keyword cloud information.
  7 in total

1.  First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Authors:  Charles L Vogel; Marek Z Wojtukiewicz; Robert R Carroll; Sergei A Tjulandin; Luis Javier Barajas-Figueroa; Brian L Wiens; Theresa A Neumann; Lee S Schwartzberg
Journal:  J Clin Oncol       Date:  2005-02-20       Impact factor: 44.544

2.  Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer.

Authors:  F A Holmes; J A O'Shaughnessy; S Vukelja; S E Jones; J Shogan; M Savin; J Glaspy; M Moore; L Meza; I Wiznitzer; T A Neumann; L R Hill; B C Liang
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 3.  Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.

Authors:  Elvira C van Dalen; Arno Mank; Edith Leclercq; Renée L Mulder; Michelle Davies; Marie José Kersten; Marianne D van de Wetering
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

4.  Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.

Authors:  Almarie Uys; Bernardo L Rapoport; Ronald Anderson
Journal:  Support Care Cancer       Date:  2004-06-09       Impact factor: 3.603

5.  Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy.

Authors:  V Trillet-Lenoir; J Green; C Manegold; J Von Pawel; U Gatzemeier; B Lebeau; A Depierre; P Johnson; G Decoster; D Tomita
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

6.  Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial.

Authors:  D W Maher; G J Lieschke; M Green; J Bishop; R Stuart-Harris; M Wolf; W P Sheridan; R F Kefford; J Cebon; I Olver; J McKendrick; G Toner; K Bradstock; M Lieschke; S Cruickshank; D K Tomita; E W Hoffman; R M Fox; G Morstyn
Journal:  Ann Intern Med       Date:  1994-10-01       Impact factor: 25.391

7.  XM02 is superior to placebo and equivalent to Neupogen in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy.

Authors:  A del Giglio; A Eniu; D Ganea-Motan; E Topuzov; H Lubenau
Journal:  BMC Cancer       Date:  2008-11-12       Impact factor: 4.430
  7 in total
  20 in total

1.  A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.

Authors:  Ari Brekkan; Luis Lopez-Lazaro; Gunnar Yngman; Elodie L Plan; Chayan Acharya; Andrew C Hooker; Suresh Kankanwadi; Mats O Karlsson
Journal:  AAPS J       Date:  2018-08-15       Impact factor: 4.009

2.  Visualization of blood cell contrast in nailfold capillaries with high-speed reverse lens mobile phone microscopy.

Authors:  Gregory N McKay; Nela Mohan; Ian Butterworth; Aurélien Bourquard; Álvaro Sánchez-Ferro; Carlos Castro-González; Nicholas J Durr
Journal:  Biomed Opt Express       Date:  2020-03-30       Impact factor: 3.732

Review 3.  Neutrophils in the Tumor Microenvironment.

Authors:  Lingyun Wu; Sugandha Saxena; Rakesh K Singh
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

4.  Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.

Authors:  Pauline Macaire; Justine Paris; Julie Vincent; François Ghiringhelli; Leïla Bengrine-Lefevre; Antonin Schmitt
Journal:  Br J Clin Pharmacol       Date:  2020-06-05       Impact factor: 4.335

5.  Timing and Outcomes of Abdominal Surgery in Neutropenic Patients.

Authors:  Joshua S Jolissaint; Maya Harary; Lily V Saadat; Arin L Madenci; Bryan V Dieffenbach; Riad H Al Natour; Ali Tavakkoli
Journal:  J Gastrointest Surg       Date:  2019-01-18       Impact factor: 3.452

6.  Intestinal Colonization Due to Carbapenem-Resistant Enterobacteriaceae Among Hematological Malignancy Patients in India: Prevalence and Molecular Charecterisation.

Authors:  Amarjeet Kumar; Sarita Mohapatra; Raunak Bir; Sonu Tyagi; Sameer Bakhshi; Manoranjan Mahapatra; Hitender Gautam; Seema Sood; Bimal Kumar Das; Arti Kapil
Journal:  Indian J Hematol Blood Transfus       Date:  2021-02-24       Impact factor: 0.900

Review 7.  GM-CSF: A Double-Edged Sword in Cancer Immunotherapy.

Authors:  Anil Kumar; Adeleh Taghi Khani; Ashly Sanchez Ortiz; Srividya Swaminathan
Journal:  Front Immunol       Date:  2022-07-05       Impact factor: 8.786

8.  Oral squamous cell carcinoma patients can be differentiated from healthy individuals with label-free serum proteomics.

Authors:  Mayank Saraswat; Antti Mäkitie; Rahul Agarwal; Sakari Joenväärä; Suvi Renkonen
Journal:  Br J Cancer       Date:  2017-06-20       Impact factor: 7.640

Review 9.  CEACAM1 as a multi-purpose target for cancer immunotherapy.

Authors:  Matthew Dankner; Scott D Gray-Owen; Yu-Hwa Huang; Richard S Blumberg; Nicole Beauchemin
Journal:  Oncoimmunology       Date:  2017-05-16       Impact factor: 8.110

10.  Multicenter study of risk factors of unplanned 30-day readmissions in pediatric oncology.

Authors:  Kamila Hoenk; Lilibeth Torno; William Feaster; Sharief Taraman; Anthony Chang; Michael Weiss; Karen Pugh; Brittney Anderson; Louis Ehwerhemuepha
Journal:  Cancer Rep (Hoboken)       Date:  2021-02-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.